CD274 and gastric cancer: However, the phase III Keynote-061 study (26) did not show significant survival benefits when pembrolizumab was used as a second-line treatment for PD-L1+ advanced GC, but improvement of OS, better efficacy, and fewer treatment related adverse events (TRAEs) were found in patients with ECOG 0, PD-L1 CPS ≥ 10, or MSI-H.